\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Joint Research CenterThe Joint Research Center (JRC), the European Commission’s science and knowledge service, has launched new calls for the purposes of open access to its scientific laboratories and facilities to people working in academia and research organisations, small and medium enterprises (SMEs) and more in general to the public and private sector. More information on this initiative can be found here or in this JRC Brochure.
It concerns the following calls:
Nanobiotechnology Laboratory - Access Call (Deadline: 21 May 2024)
MONNET, Tandem accelerator based fast neutron source (EUFRAT) – Access Call (Deadline: 30 June 2024)
HADES, Underground laboratory for ultra-low level gamma-ray spectrometry (EUFRAT) – Access Call (Deadline: 30 June 2024)
GELINA, the JRC Neutron Time-of-Flight Facility (EUFRAT) – Access Call (Deadline 30 June 2024)
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
MSCA Research Infrastructures Health Culture and society
On 11 December 2025, the European Commission has adopted the Horizon Europe Main Work Programme 2026-2027 and has published it on the EU Funding & Tenders Portal. The Work Programmes can be found under reference documents on the Funding & Tenders Portal.On the NCP Flanders website the published work programmes can be consulte... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
